XOMA Royalty (NASDAQ:XOMA) Upgraded by TD Cowen to “Hold” Rating

XOMA Royalty (NASDAQ:XOMA) was upgraded by investment analysts at TD Cowen to a “hold” rating in a research note issued to investors on Friday,Zacks.com reports.

A number of other research analysts have also issued reports on XOMA. Stifel Nicolaus set a $50.00 price objective on shares of XOMA Royalty in a report on Friday, December 12th. Wall Street Zen cut shares of XOMA Royalty from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. HC Wainwright cut their price target on shares of XOMA Royalty from $104.00 to $97.00 and set a “buy” rating on the stock in a report on Thursday, December 11th. Weiss Ratings reissued a “hold (c-)” rating on shares of XOMA Royalty in a research note on Monday, December 29th. Finally, Benchmark reaffirmed a “buy” rating on shares of XOMA Royalty in a research report on Friday, December 12th. Three research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $60.60.

XOMA Royalty Stock Up 1.9%

Shares of XOMA opened at $24.01 on Friday. The company has a debt-to-equity ratio of 1.07, a quick ratio of 3.91 and a current ratio of 3.91. XOMA Royalty has a 52 week low of $18.35 and a 52 week high of $39.92. The stock has a market capitalization of $297.24 million, a price-to-earnings ratio of 32.45 and a beta of 0.86. The stock has a fifty day moving average of $26.44 and a 200-day moving average of $31.08.

XOMA Royalty (NASDAQ:XOMA) last issued its earnings results on Wednesday, November 12th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.33). The firm had revenue of $9.35 million during the quarter, compared to analyst estimates of $11.47 million. XOMA Royalty had a return on equity of 2.91% and a net margin of 32.28%. As a group, sell-side analysts anticipate that XOMA Royalty will post -1.41 earnings per share for the current fiscal year.

Insider Buying and Selling

In other XOMA Royalty news, CEO Owen Hughes purchased 100,000 shares of the firm’s stock in a transaction on Thursday, December 4th. The stock was purchased at an average cost of $25.05 per share, for a total transaction of $2,505,000.00. Following the acquisition, the chief executive officer owned 102,000 shares in the company, valued at approximately $2,555,100. The trade was a 5,000.00% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 9.10% of the company’s stock.

Institutional Investors Weigh In On XOMA Royalty

Large investors have recently bought and sold shares of the stock. State of Alaska Department of Revenue acquired a new stake in shares of XOMA Royalty in the 4th quarter worth about $27,000. Russell Investments Group Ltd. increased its holdings in XOMA Royalty by 3,436.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 756 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in shares of XOMA Royalty by 203.1% in the second quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 1,523 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of XOMA Royalty by 13.9% in the second quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 543 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in shares of XOMA Royalty during the second quarter valued at approximately $116,000. 95.92% of the stock is currently owned by institutional investors and hedge funds.

XOMA Royalty Company Profile

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.